Activation of an Effective Immune Response after Yellow Fever Vaccination Is Associated with the Genetic Background and Early Response of IFN-γ and CLEC5A
- PMID: 33445752
- PMCID: PMC7828179
- DOI: 10.3390/v13010096
Activation of an Effective Immune Response after Yellow Fever Vaccination Is Associated with the Genetic Background and Early Response of IFN-γ and CLEC5A
Abstract
The yellow fever vaccine (YF17DD) is highly effective with a single injection conferring protection for at least 10 years. The YF17DD induces polyvalent responses, with a TH1/TH2 CD4+ profile, robust T CD8+ responses, and synthesis of interferon-gamma (IFN-γ), culminating in high titers of neutralizing antibodies. Furthermore, C-type lectin domain containing 5A (CLEC5A) has been implicated in innate outcomes in other flaviviral infections. Here, we conducted a follow-up study in volunteers immunized with YF17DD, investigating the humoral response, cellular phenotypes, gene expression, and single nucleotide polymorphisms (SNPs) of IFNG and CLEC5A, to clarify the role of these factors in early response after vaccination. Activation of CLEC5A+ monocytes occurred five days after vaccination (DAV). Following, seven DAV data showed activation of CD4+ and CD8+T cells together with early positive correlations between type II IFN and genes of innate antiviral response (STAT1, STAT2, IRF7, IRF9, OAS1, and RNASEL) as well as antibody levels. Furthermore, individuals with genotypes rs2430561 AT/AA, rs2069718 AG/AA (IFNG), and rs13237944 AC/AA (CLEC5A), exhibited higher expression of IFNG and CLEC5A, respectively. Together, we demonstrated that early IFN-γ and CLEC5A responses, associated with rs2430561, rs2069718, and rs13237944 genotypes, may be key mechanisms in the long-lasting immunity elicited by YF17DD.
Keywords: CLEC5A; interferon gamma; yellow fever vaccine.
Conflict of interest statement
The authors declare no conflict of interest.
Figures



Similar articles
-
Early IFN-gamma production after YF 17D vaccine virus immunization in mice and its association with adaptive immune responses.PLoS One. 2013 Dec 6;8(12):e81953. doi: 10.1371/journal.pone.0081953. eCollection 2013. PLoS One. 2013. PMID: 24324734 Free PMC article.
-
Adaptive immune responses to booster vaccination against yellow fever virus are much reduced compared to those after primary vaccination.Sci Rep. 2017 Apr 6;7(1):662. doi: 10.1038/s41598-017-00798-1. Sci Rep. 2017. PMID: 28386132 Free PMC article.
-
Type III Interferon-Mediated Signaling Is Critical for Controlling Live Attenuated Yellow Fever Virus Infection In Vivo.mBio. 2017 Aug 15;8(4):e00819-17. doi: 10.1128/mBio.00819-17. mBio. 2017. PMID: 28811340 Free PMC article.
-
The 17D-204 and 17DD yellow fever vaccines: an overview of major similarities and subtle differences.Expert Rev Vaccines. 2018 Jan;17(1):79-90. doi: 10.1080/14760584.2018.1406800. Epub 2017 Nov 27. Expert Rev Vaccines. 2018. PMID: 29172832 Review.
-
How to design effective vaccines: lessons from an old success story.Expert Rev Vaccines. 2009 May;8(5):543-6. doi: 10.1586/erv.09.26. Expert Rev Vaccines. 2009. PMID: 19397411 Free PMC article. Review.
Cited by
-
Differential Loss of OAS Genes Indicates Diversification of Antiviral Immunity in Mammals.Vaccines (Basel). 2023 Feb 12;11(2):419. doi: 10.3390/vaccines11020419. Vaccines (Basel). 2023. PMID: 36851296 Free PMC article.
-
Vaccines and Senior Travellers.Front Aging. 2021 Jul 9;2:677907. doi: 10.3389/fragi.2021.677907. eCollection 2021. Front Aging. 2021. PMID: 35822022 Free PMC article. Review.
-
Safety and immunogenicity following co-administration of Yellow fever vaccine with Tick-borne encephalitis or Japanese encephalitis vaccines: Results from an open label, non-randomized clinical trial.PLoS Negl Trop Dis. 2023 Feb 9;17(2):e0010616. doi: 10.1371/journal.pntd.0010616. eCollection 2023 Feb. PLoS Negl Trop Dis. 2023. PMID: 36758067 Free PMC article. Clinical Trial.
-
Mechanism of Immune Evasion in Mosquito-Borne Diseases.Pathogens. 2023 Apr 23;12(5):635. doi: 10.3390/pathogens12050635. Pathogens. 2023. PMID: 37242305 Free PMC article. Review.
-
The Involvement of CXC Motif Chemokine Ligand 10 (CXCL10) and Its Related Chemokines in the Pathogenesis of Coronary Artery Disease and in the COVID-19 Vaccination: A Narrative Review.Vaccines (Basel). 2021 Oct 21;9(11):1224. doi: 10.3390/vaccines9111224. Vaccines (Basel). 2021. PMID: 34835155 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous